Peroral Endoscopic Myotomy for Primary Esophageal Achalasia

Last updated: May 22, 2015
Sponsor: Hospices Civils de Lyon
Overall Status: Completed

Phase

3

Condition

Achalasia

Esophageal Disorders

Treatment

N/A

Clinical Study ID

NCT01560559
2011.696
  • Ages > 18
  • All Genders

Study Summary

Recommended therapies for esophageal achalasia are endoscopic pneumatic dilation and Heller-Dor surgical myotomy. Endoscopic myotomy has been recently proposed in human patient in expert centers in Japan, US and Germany. In theory, endoscopic myotomy is as effective as surgical myotomy but less invasive and more effective with less complications than endoscopic pneumatic dilation. Up to now, published studies have confirmed these expectations, with 100% efficacy and no clinically significant complications. The present clinical trial with study the security and efficacy of peroral endoscopic myotomy in primary achalasia patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients of both sexes aged over 18 years old

  2. Patients who have signed the informed consent form before any study related procedure

  3. Primary achalasia of the cardia with Eckardt score > 3

  4. Non sigmoid achalasia or S1 sigmoid type achalasia at barium meal Rx study

  5. ASA score (American Society of Anaesthesiologists) 1 or 2

  6. Patients affiliated to a social security health system

Exclusion

Exclusion Criteria:

  1. Patients with age less than 18 years old

  2. Patients without discernment with legal protection

  3. Patients who will not be able to abide with study follow-up as judged by theinvestigator

  4. Patients which cannot provide a written informed consent

  5. Patient refusing to participate in the study, without informed consent

  6. Pregnant or breastfeeding women, women in fertile age for procreation withoutefficient contraception, and/or positive serum βHCG test

  7. Concomitant participation in other clinical trial

  8. S2 sigmoid type primitive achalasia of the cardia

  9. Pseudo-achalasia (esophageal carcinoma),

  10. History of Barrett's esophagus with or without dysplasia, malignant tumors of theesophagus

  11. History of esophageal strictures, systemic sclerosis

  12. History of esophageal varices

  13. History of endoscopic or surgical therapy of the esophageal achalasia

  14. History of inferior endoscopic or surgical esophageal sphincter manipulation (sutures,polymers injection, adhesive bands)

  15. History of surgical interventions of the esophagus or stomach (fundoplication,Heller-Dor myotomy, gastric resections, vagotomy with or without gastric drainage)

  16. History of congenital of acquired coagulation anomalies: hemorrhagic diseases,hemostasis disturbances (TP < 60%, TCA > 40 seconds, platelets < 60000/mmc)

  17. ASA score (American Society of Anaesthesiologists) 3, 4, 5 or 6

  18. Cancer, liver, respiratory, renal or heart failure which put the patients in the ASArisk group 3,4,5 or 6.

Study Design

Total Participants: 16
Study Start date:
March 01, 2012
Estimated Completion Date:
January 31, 2015

Connect with a study center

  • Clinique de Hépatogastroentérologie

    Lyon, 69003
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.